Research programme: allosteric kinase inhibitors - Kemia
Latest Information Update: 06 Dec 2010
At a glance
- Originator Kemia
- Mechanism of Action Phosphotransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 27 Feb 2008 Early research in Undefined indication in USA (unspecified route)
- 27 Feb 2008 Research programme is available for licensing in USA (http://www.kemia.com)